Article Text

other Versions

PDF
Comparison of the BASDAI and the modified BASDAI (mini-BASDAI) in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations
  1. I H Song (in-ho.song{at}charite.de)
  1. Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    1. M Rudwaleit (martin.rudwaleit{at}charite.de)
    1. Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
      1. J Listing (listing{at}drfz.de)
      1. German Rheumatism Research Centre, Germany
        1. J Sieper (joachim.sieper{at}charite.de)
        1. Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany

          Abstract

          Objective: To compare the original Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with a modified-BASDAI without questions about peripheral arthritis (question 3) and enthesitis (question 4), here termed the mini-BASDAI, as an instrument to assess disease activity in patients with ankylosing spondylitis (AS) without peripheral manifestations.

          Methods: The mini-BASDAI was calculated by omitting questions 3 and 4. The correlation of the original BASDAI and the mini-BASDAI with patient global and other disease parameters was assessed in a total of 692 patients from three AS cohorts including one observational AS cohort and two clinical trial populations treated with NSAIDs and TNFα-inhibitors. Sensitivity to change was assessed by calculating effect sizes.

          Results: Up to 70% of AS patients did not have peripheral involvement. Patients with peripheral involvement had higher disease activity in all activity parameters. The mini-BASDAI had higher values compared to the original BASDAI, also in the subgroup with peripheral manifestations. However, the mini-BASDAI did not better correlate with other markers of disease activity compared to the original BASDAI. Furthermore, effect sizes of the original BASDAI and mini-BASDAI were comparable in the treatment trials. Interestingly, we identified about 5% of active AS patients with pure axial disease manifestation whose disease activity was underestimated by the original BASDAI.

          Conclusion: On a group level using the mini-BASDAI did not result in an advantage to assess disease activity also not in the subgroup without peripheral involvement. In only about 5% of AS patients the mini-BASDAI was superior to the original BASDAI.

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.